ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0306

Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis

Misako Higashida-Konishi1, Keisuke Izumi2, Tatsuya Shimada3, Satoshi Hama4, Mitsuhiro Akiyama5, Hisaji Oshima4 and Yutaka Okano6, 1Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguroku, Japan, 2Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 4Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, 5Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Palo Alto, CA, 6Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan

Meeting: ACR Convergence 2021

Keywords: Autoantibody(ies), autoimmune diseases, Drug toxicity, rheumatoid arthritis, Sjögren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren’s syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.

We aimed to compare the prevalence of allergic disorders in pSS and rheumatoid arthritis (RA) ,and to compare the clinical features at diagnosis of pSS with and without drug allergies.

Methods: We retrospectively examined consecutive patients diagnosed with pSS or RA in our hospital from 2010 to 2020. The patients with SS met the criteria of the 1999 revised Japanese Ministry of Health criteria [2]. We included patients with pSS without RA or other rheumatic diseases. The patients with RA met the EULAR/ACR 2010 criteria. We included patients with RA without other rheumatic diseases.

The first analysis was performed on five types of allergic reactions: (1) food allergy (exanthema, angioedema and anaphylaxis after foods exposure), (2) drug allergy (exanthema, angioedema and anaphylaxis after drug exposure), (3) allergic contact dermatitis such as metals, alcohol swab, and other cosmetics, (4) seasonal allergic rhinitis and/or allergic conjunctivitis, and allergic rhinitis and/or allergic conjunctivitis associated with house dust, and (5) asthma.

The secondary analysis was performed on patient baseline laboratory data at diagnosis of pSS and RA patients with or without drug allergies.

Results: In the first analysis, 292 patients with pSS and 413 patients with RA were enrolled (Table 1). The mean ages (pSS, RA) were 57.3±15.8, 66.0±14.6 years old. Females were 94.2% , 78.2%. The mean observation period was 82.7±70.8, 65.6±37.0 months. 54.8% of pSS patients and 34.9% of RA patients presented at least one type of allergic disorders or drug allergies. These included food allergy, drug allergy, allergic rhinitis/conjunctivitis, and asthma. Allergic disorders and drug allergies were more frequent in patients with pSS.

In the second analysis, 77 patients with drug allergies and 215 patients without drug allergies were enrolled (Table 2). The mean ages with drug allergies and without drug allergies were 56.0±15.8 and 57.8±15.8 years old, respectively; females were 96.1% and 93.5%; the mean observation period was 90.9±72.4 and 79.8±70.2 months (Table 2). The pSS patients with drug allergies had higher levels of Immunoglobulin G (IgG) (p = 0.01), higher levels of eosinophils (p< 0.019), and higher positivity rate of anti–Sjögren's-syndrome-related antigen A autoantibody (anti-SSA antibody) than those without drug allergies (p = 0.06) (Table 2).

Conclusion: Patients with pSS had a higher prevalence of allergic disorders and drug allergies than patients with RA. Among patients with pSS, patients with drug allergies had higher levels of IgG, higher levels of eosinophils, and higher positivity rate of anti-SSA antibody than those without drug allergies.

[1] Hama et al. Clinical features of patients with Sjoegren syndrome associated with adult onset Still’s disease. Japan College of Rheumatology Annual Congress 2020.
[2] Fujibayashi et al. Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod Rheumatol. 2004; 14: 425-34 .


Disclosures: M. Higashida-Konishi, None; K. Izumi, None; T. Shimada, None; S. Hama, None; M. Akiyama, None; H. Oshima, None; Y. Okano, None.

To cite this abstract in AMA style:

Higashida-Konishi M, Izumi K, Shimada T, Hama S, Akiyama M, Oshima H, Okano Y. Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/allergic-disorders-in-primary-sjogrens-syndrome-compared-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/allergic-disorders-in-primary-sjogrens-syndrome-compared-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology